Even after decades of research, there is no cure for the disease HIV causes, AIDS. But lenacapavir, born out of research on ...

Gilead Sciences’ long-acting drug to block HIV can end the AIDS epidemic worldwide. But accessibility is the question. © 2025 American City Business Journals. All ...

Announcing a new publication for Acta Materia Medica journal. The HIV-1 capsid protein (CA) plays a crucial role in viral ...

O'Day emphasized the upcoming FDA decision for Lenacapavir for PrEP, expected by June 19, 2025, and its potential launch in the U.S. shortly thereafter. This is one of nine HIV product launches ...

Leading data and analytics company GlobalData’s report, Human Immunodeficiency Virus (HIV): Seven-Market Drug Forecast, ...

There are several ways to address HIV in homeless populations, with the most promising being the low barrier care model, ...

Adjusted profit $1.81 per share vs analyst estimates of $1.79 Company says FDA lenacapavir review still expected by June 19 Biktarvy sales rise 7%, cell therapy sales fall 3% April 24 (Reuters) - ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales ...

The global HIV market is expected to reach $32.1 billion by 2033, driven by long-acting injectables and innovative therapies, ...

is being recognized with his co-recipient, Tomas Cihlar, a virologist for Gilead Sciences, for their work that led to a first-of-its-kind HIV treatment and prevention drug lenacapavir. Time ...

Gilead Sciences’ long-acting drug to block HIV could end the AIDS epidemic worldwide. But access and funding remain big questions. Bay Area Biotech Forum The Future of Bay Area Biotech ...